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Salut. Universitat de Barcelona (UB), 08036 Barcelona, SpainOncolytic viruses are designed for cancer treatment. Cell-virus
interactions are key determinants for successful viral replica-
tion. Therefore, the extensive reprogramming of gene expres-
sion that occurs in tumor cells might create a hurdle for
viral propagation. We used a replication-based approach of a
microRNA (miRNA) adenoviral library encoding up to 243 hu-
man miRNAs as a bioselection strategy to identify miRNAs
that facilitate adenoviral oncolytic activity in pancreatic ductal
adenocarcinoma. We identify two miRNAs, miR-99b and miR-
485, that function as enhancers of adenoviral oncolysis by
improving the intra- and extracellular yield of mature virions.
An increased adenoviral activity is the consequence of
enhanced E1A and late viral protein expression, which is prob-
ably mediated by the downregulation of the transcriptional
repressors ELF4, MDM2, and KLF8, which we identify as
miR-99b or miR-485 target genes. Arming the oncolytic adeno-
virus ICOVIR15 with miR-99b or miR-485 enhances its fitness
and its antitumoral activity. Our results demonstrate the po-
tential of this strategy to improve oncolytic adenovirus po-
tency, and they highlight miR-99b and miR-485 as sensitizers
of adenoviral replication.Received 23 April 2018; accepted 20 September 2018;
https://doi.org/10.1016/j.ymthe.2018.09.016.
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Viruses have evolved a number of strategies to hijack cellular re-
sources, forcing them to synthesize new virions for a successful viral
propagation.1,2 These strategies have been acquired as a conse-
quence of an adaptive process in specific cellular contexts. While
the use of viruses in cancer treatments has long been studied,3 tu-
mor cells present a number of genetic alterations that elicit massive
reprogramming of cellular gene expression, creating a novel context
in which viruses have not adapted to replicate.4 The inherent
complexity of tumors makes the oncolytic viral activity highly
dependent on the specific characteristics of tumor cells. In fact,
the differential expression of certain genes in cancer cells can nega-
tively impact viral replication.5–7 Nevertheless, molecular mecha-
nisms explaining viral replication heterogeneity in cancer cells
remain to be fully appraised.8230 Molecular Therapy Vol. 27 No 1 January 2019 ª 2018 The AmericMicroRNAs (miRNAs) are post-transcriptional negative regulators of
gene expression that modulate a variety of cellular physiological pro-
cesses. miRNAs also play important roles in host-virus interactions.9
Viral infections can modulate the cellular miRNome with changes
induced either by the virus, to promote a proviral environment, or
by the antiviral cellular response, to limit the viral life cycle.10–12
Although the mechanisms of miRNA-mediated regulation of viral
infection have not been completely clarified, it is clear that host
miRNAs can regulate viral infections.
In the context of tumorigenesis, many miRNAs with essential roles in
cancer-associated pathways are dysregulated.13 Participation of
miRNAs has been demonstrated in central cancer processes, such
as cell proliferation and death, cell differentiation, and maintenance
of stem cell potency.14 Aberrant expression of miRNAs has been
well documented for pancreatic ductal adenocarcinoma (PDAC),
and specific miRNA signatures have been associated with diagnosis,
staging, progression, prognosis, and treatment response.15,16 Hence,
when viruses are used as oncolytic agents, they face an already per-
turbed miRNome in cancer cells. These miRNA profile changes
may not necessarily favor viral replication and propagation within
the tumor; indeed, the downregulation of certain miRNAs could
induce the overexpression of viral-limiting factors.
Adenoviruses (Ads) are non-enveloped icosahedral viruses with dou-
ble-stranded DNA genomes. The viral genome is sub-divided into
regions termed early and late according to when transcription activa-
tion initiates. Early genes remodel the intracellular environment to
prepare the cell for viral replication and activate the expression of
other viral genes. Late genes primarily constitute viral structural pro-





















































































































































Figure 1. miR-99b and miR-485 Identified through a Bioselection Strategy as Enhancers of the Adenoviral Replication
(A) Schematic representation of the miRNA adenoviral library bioselection procedure. 243 human miRNAs under the control of a CMV promoter were cloned into the
adenoviral genome (between the E4 gene and R-ITR) to generate a library (AdwtE miRLib). The library was bioselected through a replication-based strategy in PANC-1 and
MIA PaCa-2 cell lines (see the Materials and Methods for a detailed description). As viruses encoding miR-99b and miR-485 were bioselected in both cell lines, they were
(legend continued on next page)
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Molecular Therapyengineered as oncolytic agents for therapeutics against different can-
cer types, including PDAC.17,18 Upon adenoviral infection, cellular
miRNA profiles suffer profound changes that influence viral replica-
tion.10,11,19 For this reason, dysregulated miRNA profiles in cancer
cells may generate an inadequate environment for adenoviral activity.
Recently, Hodzic and coworkers11 identified a group of miRNAs that
sensitize cells to Ad5-induced cell death. However, several of these
miRNAs triggered premature cell death that interfered with the
adenoviral cycle, and only miR-26b was found to be an enhancer of
Ad5 propagation. Intriguingly, and contrary to what was expected,
miR-26b was highly expressed in PC-3 cells, and Ad5 infection
only caused a slight reduction of its expression, thus confirming the
complexity of miRNA-virus interactions.11
Here we describe the identification of human miRNAs that favor
adenoviral activity in pancreatic cancer, using a replication-based bio-
selection strategy. We identified miR-99b and miR-485 as enhancers
of the adenovirally mediated oncolysis in PDAC, whereby they facil-
itate the formation of mature virions by means of negatively regu-
lating the expression of specific transcription factors. Arming the
ICOVIR15 oncolytic adenovirus with miR-99b or miR-485 resulted
in new viruses that greatly improved the antitumor efficacy. We
believe that this approach could be used to bypass the complexity
of the host-virus interactions, as miRNA sequences are codified
directly within the adenoviral genome, giving rise to a single thera-
peutic agent.
RESULTS
In Vitro Bioselection of the miRNA Adenoviral Library AdwtE
miRLib in PDAC Cell Lines
To identify miRNAs that enhance adenoviral activity, we generated
a miRNA adenoviral library (AdwtE miRLib). The AdwtE miRLib
consisted of a pool of adenoviruses coding for up to 243 different hu-
man primary miRNA (pri-miRNA) genomic sequences under the
control of the cytomegalovirus (CMV) promoter. These sequences
were introduced next to the right inverted terminal repeat (R-ITR)
of a wild-type adenovirus 5 expressing the EGFP gene under the con-
trol of the major later promoter (MLP) (AdwtE) (Figure 1A). The
AdwtE miRLib was subjected to 20 rounds of bioselection in
PANC-1 and MIA PaCa-2 PDAC cell lines. After this, adenoviral
clones were isolated by the plaque assay, and the miRNAs present
were identified by Sanger sequencing (Figure 1A). Although several
miRNAs were detected to be enriched following PANC-1 and MIA
PaCa-2 bioselection, adenoviruses encoding miR-99b and miR-485
were enriched in the two cell lines (Figure 1A; Table S1). In MIAchosen for further validation. (B) Schematic representation of the candidate viruses, Ad
(C and D) Expression of miR-99b (5p and 3p) (C) andmiR-485 (5p and 3p) (D) in PANC-1
(E and F) AdwtE miR-99b and AdwtE miR-485 activity. PANC-1 (E) and MIA PaCa-2 (F)
99b, AdwtE miR-485, or AdwtE hTR. At 48 hr PI, virus-containing supernatants were co
procedure was repeated for three sequential steps. EGFP expression was analyzed an
Representative images are shown. Original magnification 4; scale bar, 200 mm. Data
nificance was assessed using a two-tailedMann-Whitney test (C and D) and by comparis
using a two-tailed Mann-Whitney test (E and F). *p < 0.05, **p < 0.01.
232 Molecular Therapy Vol. 27 No 1 January 2019PaCa-2 cells, clones coding for miR-99b were highly enriched with
respect to the total number of clones encoding for a given miRNA
(87.9%), whereas miR-485 was less represented (9.1%). In PANC-1
cells, the most abundant miRNA-encoding represented clone was
miR-485 (28.6%), with miR-99b encoded in fewer clones (7.1%).
Next, we took advantage of the miRNome profile of 11 PDAC and 3
normal pancreatic tissues, performed by next-generation sequencing
(NGS) (Illumina Genome Analyzer), in the context of a previous
study focused on the identification of miRNA biomarkers for early
disease detection.15 Analysis of miR-99b and miR-485 in this NGS
dataset revealed that both miRNAs’ 30 arms (3p), miR-99b-3p and
miR-485-3p, were significantly downregulated in PDAC tumors (Fig-
ure S1A). Using The Cancer Genome Atlas (TCGA) dataset (https://
tcga-data.nci.nih.gov/docs/publications/tcga/?), we classified patients
into groups with high or low expression for each miRNA, and we
evaluated relative survival. Interestingly, low miRNA expression of
both miRNAs correlated with poor clinical outcome (Figures S1B
and S1C). These results suggest that miR-99b and miR-485 may
play a role in PDAC tumorigenesis.
Together, the data suggest that miR-99b and miR-485 may be poten-
tial regulators of the host response to adenoviral activity. Thus, we
considered AdwtE miR-99b and AdwtE miR-485 to be good candi-
dates for further characterization.
Viruses Encoding miR-99b or miR-485 Have Increased Activity
in PDAC
Adenoviral clones encoding either miR-99b or miR-485 were
selected, expanded, and purified to generate AdwtE miR-99b and
AdwtE miR-485. Two control viruses were also generated: the
parental virus (AdwtE) and a similar-sized virus of AdwtE miR en-
coding the human telomerase RNA (hTR) (AdwtE hTR) (Figure 1B).
To verify that candidate miRNAs were expressed from AdwtE miR-
99b and AdwtE miR-485 viruses, PANC-1 cells were infected with
the corresponding viruses; after 24 hr, specific expression of the cor-
responding miRNAs was analyzed. We determined that both the 30
arm (3p) and the 50 arm (5p) of the miRNA chains were overex-
pressed, indicating that candidate miRNAs were correctly processed
from the viral genome (Figures 1C and 1D).
Next, we examined AdwtE miR-99b and AdwtE miR-485 viral activ-
ities in PANC-1 and MIA PaCa-2 cells in comparison to the control
viruses (AdwtE and AdwtE hTR). For this, cells were exposed to threewtE miR-99b and AdwtE miR-485, and the control viruses, AdwtE and AdwtE hTR.
cells at 24 hr PI with mock or 10 IFU/cell AdwtE, AdwtEmiR-99b, or AdwtEmiR-485.
cells were infected (at 1 IFU/cell or 5 IFU/cell, respectively) with AdwtE, AdwtE miR-
llected and used to infect new cells (10% for PANC-1 and 50% for MIA PaCa-2). The
d quantified at the end of each infection. The dashed line represents AdwtE values.
are shown as mean ± SEM for at least five independent biological replicates. Sig-
on to AdwtE-infected cells using a one-sample t test and to AdwtE hTR infected cells
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Figure 2. AdwtE miR-99b and AdwtE miR-485 Viruses Have Viral Activity
Superior to the Parental Virus AdwtE in an In Vivo Context
(A) Scheme of the in vivo competition assay. Mice bearing subcutaneous PANC-1
and MIA PaCa-2 tumors were intravenously administered a 1:1 mixture of
AdwtE:AdwtE miR-99b or AdwtE:AdwtE miR-485 (2  1010 vp/animal). Tumors
were recovered at 12 days PI and the infective viral particles of each virus were
quantified. (B and C) Infective viral particle quantification at the end of
the competition assay in (B) PANC-1 tumors treated with AdwtE:AdwtE miR-99b
(n = 7) or AdwtE:AdwtE miR-485 (n = 10) or in (C) MIA PaCa-2 tumors treated with
AdwtE:AdwtE miR-99b (n = 8) or AdwtE:AdwtE miR-485 (n = 4). Data are
shown as mean ± SEM. Significance was assessed by comparison to AdwtE
infective particles present in tumors using a two-tailed Mann-Whitney test.
*p < 0.05, **p < 0.01, ***p < 0.001.
www.moleculartherapy.orgconsecutive rounds of infection, and EGFP fluorescence levels were
evaluated at the end of each infection. Cells infected with the two
AdwtE miR viruses displayed higher EGFP levels after the first round,
which increased throughout the infection rounds, reaching levels
10-fold higher than AdwtE in PANC-1 cells and 4-fold higher than
AdwtE in MIA PaCa-2 cells (Figures 1E and 1F). Similar results
were obtained in CP15-Luc, NP-18, Capan-2, HPAF-II, and
Hs766T PDAC cells (Figure S2A).
To assess if the enhanced in vitro activity of AdwtE miR viruses
could also be recapitulated in vivo, we performed an in vivo compe-
tition assay. Animals with subcutaneous PANC-1 or MIA PaCa-2
tumors in the lateral flanks received a mixture of 1:1 AdwtE:AdwtE
miR-99b or AdwtE:AdwtE miR-485 through the lateral tail vein. Af-
ter 12 days, the amount of infective particles of each virus present in
the tumors was quantified (Figure 2A). Adenoviruses encoding
either of the miRNA candidates were more abundant in both
PANC-1 and MIA PaCa-2 tumors (Figures 2B and 2C). In
PANC-1 tumors, AdwtE miR-485 was up to 10-fold superior to
AdwtE, while AdwtE miR-99b replicated only 2-fold more than
AdwtE (Figure 2B). These results coincide with the bioselection
approach in which AdwtE miR-485 was the most represented clone
in PANC-1 cells (Table S1). In MIA PaCa-2 tumors, miR-99b and
miR-485 similarly improved AdwtE fitness by 4-fold (Figure 2C).
These results suggest that miR-99b- and miR-485-encoding viruses
may trigger a more potent antitumoral activity than the parental un-
modified virus.
miR-99b and miR-485 Expression Enhances Infective Viral
Particle Formation, Viral Release, and In Vitro Cytotoxicity
To evaluate the effects of miR-99b and miR-485 on adenoviral repli-
cation, PANC-1 and MIA PaCa-2 cells were infected with AdwtE
miR-99b and AdwtEmiR-485 at a low viral dose; after one replication
cycle, the concentration of infective viral particles present in the su-
pernatant was determined, as stated and at 4 hr after infection to
ensure equal viral entry between viruses. Indeed, both miRNAs led
to higher numbers of released infective particles compared to AdwtE
(Figure 3A). This effect was dose dependent. Differences between
AdwtE miR viruses and AdwtE diminished at higher infecting doses
(Figure 3B), suggesting a saturation effect, where all the viruses
already reached the maximum effects.
To confirm that the increase in released infective particles was specific
for miR-99b and miR-485 activity, PANC-1 cells were transfected
with miRNA expression plasmids (miRVec-99b or miRVec-485) or
a control plasmid (miRVec hTR), followed by AdwtE infection. The
release of AdwtE infective particles was increased in the presence of
either miRNA (Figure S3A). Furthermore, infection of PANC-1 cells
with AdwtE miR-759, a miRNA that remains stable during adeno-
virus infection,10,11 resulted in a viral release similar to that of the con-
trol viruses AdwtE and AdwtE hTR (Figure S3B), indicating that the
observed effects of candidate miRNAs were specific and not due to
universal miRNA effects, such as a block in the miRNA biogenesis
pathway.Molecular Therapy Vol. 27 No 1 January 2019 233
AdwtE 0,181 ± 0,023
AdwtE miR-99b 0,099 ± 0,013 (0,0043)
AdwtE miR-485 0,058 ± 0,008 (0,0260)
AdwtE 0,903 ± 0,099
AdwtE miR-99b 0,548 ± 0,044 (0,0023)
AdwtE miR-485 0,682 ± 0,049 (0,0082)
MIA PaCa-2
IC50 ± SEM (P value)























































































































































































Figure 3. miR-99b- and miR-485-Encoding Adenoviruses Display Higher Viral Yield, Correlating with Increased In Vitro Oncolytic Activity
(A) Relative infective viral particle release. PANC-1 and MIA PaCa-2 cells were seeded in triplicate and infected (at 0.5 IFU/cell or 5 IFU/cell, respectively) with AdwtE, AdwtE
miR-99b, or AdwtE miR-485. At 48 hr PI, supernatants were collected and titrated by viral infectious units. The dashed line represents AdwtE values. (B) Dose dependence
effect on infective viral particles released in PANC-1 cells. Cells were seeded in triplicate and infected with AdwtE, AdwtE miR-99b, or AdwtE miR-485 at a range of doses. At
48 hr PI, supernatants were collected and titrated by viral infectious units. The dashed line represents AdwtE values. (C) Time course of intra- and extracellular infective viral
particles in PANC-1 cells. Cells were seeded in triplicate and infected with AdwtE, AdwtE miR-99b, or AdwtE miR-485 at a dose of 0.5 IFU/cell. Cells and supernatants were
collected at 24, 30, 48, and 72 hr PI and titrated by viral infectious units. (D) Time course of total intracellular viral genome content in PANC-1 cells. Cells were seeded in
triplicate and infected with AdwtE, AdwtE miR-99b, or AdwtE miR-485 at a dose of 0.5 IFU/cell. Cells were collected at 24, 30, 48, and 72 hr PI, and the intracellular viral
(legend continued on next page)
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www.moleculartherapy.orgWe next investigated whether the increase in the number of infective
particles in the supernatants was due to an enhanced viral release or to
an increase in the number of intracellular particles. PANC-1 cells
were infected with AdwtE, AdwtE miR-99b, or AdwtE miR-485,
and the amounts of infective viral particles present in the intracellular
and extracellular compartments were measured at the indicated time
points. Infection with AdwtE miR-99b or AdwtE miR-485 led to a
faster release of infective viral particles than did AdwtE. This higher
release correlated with a more efficient intracellular content of AdwtE
miR infective particles (Figure 3C). In contrast, quantification of
intracellular viral genomes showed no differences between viruses
at early time points. An increase in the number of intracellular viral
genomes was observed at 72 hr post-infection (PI), probably due to
the internalization of viral genomes in a second infection cycle
(Figure 3D).
The increase in the viral release of AdwtE miR-99b and AdwtE miR-
485 led to an enhanced cytotoxic activity, with AdwtE miR-485
leading to a 3-fold decrease in the IC50 values in PANC-1 cells and
to a 2-fold decrease in MIA PaCa-2 cells. Similarly, AdwtE miR-
99b promoted a 2-fold decrease in the IC50 in both cell lines (Fig-
ure 3E). AdwtE miR-485 and AdwtE miR-99b also had significantly
reduced IC50 values in CP15-Luc, NP-18, Capan-2, HPAF-II, and
Hs766T PDAC cells (Figure S2B). Altogether, these results establish
that miR-99b and miR-485 increase the adenoviral fitness through
an enhancement in the intracellular content and release of mature
virions, thereby conferring increased cytotoxicity to miR candidate-
encoding viruses.
miR-99b and miR-485 Increase the Expression of Viral Genes
To further characterize AdwtE miR-99b and AdwtE miR-485, we
analyzed the mRNA levels of late (hexon and fiber) and immediate
early (E1A) genes at 24 or 8 hr PI, respectively, in PANC-1 and
MIA PaCa-2 cells. Increased mRNA levels of the three genes were
observed in AdwtE miR-infected cells (Figures 4A and 4B). Consis-
tent with these results, higher protein contents of hexon, penton,
fiber, and E1A were also detected (Figures 4C and 4D). These results
suggest that miR-99b and miR-485 may modulate cellular pathways,
affecting both early and late transcription of viral genes.
miR-99b andmiR-485 Inhibit the Expression of Genes Related to
Transcription Regulation
We next performed a bioinformatics study to elucidate the mecha-
nisms by which miR-99b andmiR-485 regulate the expression of viral
genes (Supplemental Materials and Methods; Figure S4A). The list of
potential target genes for miR-99b and miR-485, generated by
different miRwalk prediction algorithms, was classified by the biolog-
ical process subontology of gene ontology (GO) terms. One of the en-
riched GO terms that was common to both miRNAs and interestinggenomes were quantified by qPCR. (E) In vitro oncolytic activity in PANC-1 and MIA Pa
AdwtEmiR-99b, or AdwtEmiR-485. Cell viability wasmeasured 7 days PI by (3-(4,5-dim
determined. Data are shown asmean ±SEM for at least five independent biological replic
tailed Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001.in light of the experimental data was “regulation of gene expression.”
Among the genes belonging to this term, we selected those with
better prediction scores as targets for miR-99b and miR-485
(Table S2), which we could infer from published data also possessed
some activity modulating viral infections or the adenoviral cycle.
Thus, we selected the transcriptional regulators E74-like ETS tran-
scription factor 4 (ELF4) and Kruppel-like factor 8 (KLF8), both
of which have predicted target sites for miR-99b and miR-485,
and MDM2 proto-oncogene (MDM2), a miR-485-validated target
gene20 (Figures S4B and S5).
We first investigated whether ELF4, MDM2, and KLF8 gene expres-
sion was regulated by the candidate miRNAs. PANC-1 cells were
mock infected or infected with control or AdwtE miR viruses, and
both mRNA and protein levels were analyzed. Reduction in the
ELF4 mRNA and protein levels was observed only in AdwtE miR-
99b-infected cells (Figures 5A and 5B). Thus, although ELF4 had a
miR-485 prediction site (Figure S4B), we could not validate any effect
in our experimental setting. MDM2 expression was significantly
reduced in cells infected with either AdwtE miR-485 or AdwtE
miR-99b (Figures 5A and 5B). The reduced expression observed after
AdwtE miR-99b was unexpected, as MDM2 is not a direct target of
miR-99b (Figure S4B). However, MDM2 downregulation could be
mediated by limited transcription due to the decrease in its transcrip-
tional regulator ELF4 or by other indirect mechanisms.21 KLF8
expression was significantly reduced in cells infected with either of
the miR candidate viruses, as predicted, although it could be detected
only at the protein level (Figures 5A and 5B).
MDM2 is a known miR-485 target.20 To validate the miR-99b
target site for ELF4 and the miR-99b and miR-485 target sites
for KLF8, we performed reporter assays. A fragment of the ELF4
or KLF8 30 UTR, which contains predicted wild-type or mutated
miR-binding sites (Figure S5), was cloned into a dual luciferase re-
porter construct and co-transfected into HEK293T cells with
miRVec-99b or miRVec-485 expression plasmids. As shown in Fig-
ure 5C, Renilla activity was significantly decreased for ELF4 wild-
type 30 UTR with miR-99b and for KLF8 wild-type 30 UTR with
miR-99b and miR-485. These effects were not observed when
miR-binding sites were mutated (Figure 5C; Figure S5). These
data confirmed the regulation of ELF4 by miR-99b and of KLF8
by both miR-99b and miR-485.
These results suggest that miR-99b and/or miR-485 modulation of
ELF4 and KLF8 could affect adenoviral replication. To test this, we
generated ELF4 and KLF8 knockdown PANC-1 cells and infected
them with AdwtE. Indeed, AdwtE-infected cells released higher levels
of infective particles in all clones with reduced expression of ELF4 or
KLF8 (Figures 5D and 5E; Figure S6), thus validating our hypothesis.Ca-2 cells. Cells were seeded in triplicate and infected with a dose range of AdwtE,
ethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay and IC50 values were
ates. Significance was assessed by comparison to AdwtE-infected cells using a two-





















































































































































































































Figure 4. The Increase in AdwtEmiR-99b and AdwtE
miR-485 Infective Particles Is Facilitated by Higher
Expression Levels of Viral Genes
(A and B) qPCR analysis of hexon, fiber (24 hr PI) (A), and
E1A (8 hr PI) (B) mRNA levels in PANC-1 and MIA PaCa-2
cells infected (at 1 and 5 IFU/cell, respectively) with AdwtE,
AdwtE miR-99b, or AdwtE miR-485. mRNA values are
given relative to cellular GAPDH in each replicate. The
dashed line represents AdwtE values. (C and D) Quantifi-
cation of hexon, penton, fiber (24 hr PI) (C), and E1A (8 hr PI)
(D) protein levels in PANC-1 andMIA PaCa-2 cells infected
(at 1 and 5 IFU/cell, respectively) with AdwtE, AdwtE miR-
99b, or AdwtE miR-485. Representative western blot im-
ages are shown. Quantification of signal was normalized to
cellular GAPDH in each replicate. The dashed line repre-
sents AdwtE values. Data are shown as mean ± SEM for at
least four independent biological replicates. Significance
was assessed by comparison toAdwtE-infected cells using
a one-sample t test. *p < 0.05, **p < 0.01, ***p < 0.001.
Molecular TherapymiR-99b and miR-485 Confer a Superior In Vitro and In Vivo
Activity to the Oncoselective Adenovirus ICOVIR15
We next evaluated whether the improved adenoviral fitness triggered
by miR-99b andmiR-485 translates into enhanced antitumor activity.
To this end, we armed ICOVIR15 with the candidate miRNAs.
ICOVIR15 is an Ad5 derivative oncolytic adenovirus that keeps intact
all the virus functions, with modifications in the E1A and fiber genes.
The E1A region contains a 24-bp deletion and incorporates E2F-
responsive elements to redirect E1A transcription toward deregula-
tion of the Rb/p16 pathway. The fiber contains an RGDmotif inserted
in the HI-loop region.22
miR-99b and miR-485 human genomic sequences were incorporated
into an ICOVIR15 genome under a CMV promoter next to the
R-ITR. First, we tested the in vitro activity of these miR candidate-en-
coding viruses. In line with previous results with AdwtE miR viruses,236 Molecular Therapy Vol. 27 No 1 January 2019ICOVIR15 miR-99b and ICOVIR15 miR-485
displayed a significant increase in infective par-
ticles released from PANC-1 cells, and they had
a 2-fold increase in cytotoxicity as compared to
the parental virus ICOVIR15 (Figures 6A and
6B). Similar data were obtained from MIA
PaCa-2 cells (Figure S7).
To evaluate the antitumor effects of ICOVIR15
miR viruses, mice with subcutaneous PANC-1
tumors were treated with a systemic dose of sa-
line solution, ICOVIR15, ICOVIR15 miR-99b,
or ICOVIR15 miR-485 at 4 1010 viral particles
(vp)/animal. Treatment with ICOVIR15 miR vi-
ruses strongly inhibited tumor growth that was
consistently higher than inhibition observed us-
ing the parental ICOVIR15 (Figure 6C). Interest-
ingly, ICOVIR15 miR viruses administeredat 2  1010 vp/animal displayed the same antitumoral activity as
ICOVIR15 administered at the double dose (4 1010 vp/animal) (Fig-
ure 6D). The presence of replicating active adenovirus in tumors was
determined by analyzing E1A expression by qRT-PCR and by immu-
nostaining at the end of the experiment. Tumors treated with
ICOVIR15 miR viruses, and especially with ICOVIR15 miR-485, dis-
played increased E1AmRNA levels (Figure 6E). Larger areas of adeno-
virus replication were also observed in the tumors that were treated
with ICOVIR15 miR viruses (Figure 6F). These data strongly suggest
that miR-99b andmiR-485 confer enhanced potency to the ICOVIR15
oncolytic adenovirus through increased adenoviral release.
DISCUSSION
Oncolytic adenoviruses are therapeutics under clinical development.
Nonetheless, although they display good safety profiles, their onco-






















































































































































































































Figure 5. miR-99b and miR-485 Downregulate
Genes Involved in Transcriptional Regulation
(A) qPCR analysis of ELF4,MDM2, andKLF8mRNA levels
in PANC-1 cells at 24 hr PI with mock or 10 IFU/cell
AdwtE, AdwtE miR-99b, or AdwtE miR-485. mRNA
values are expressed relative to cellular GAPDH in each
replicate. The dashed line represents mock-infected
values. (B) Quantification of ELF4, MDM2, and KLF8
mRNA levels in PANC-1 cells at 24 hr PI with mock or 10
IFU/cell AdwtE, AdwtE miR-99b, AdwtE miR-485, or
AdwtE hTR. Representative western blot images are
shown. Quantification of signal was normalized to cellular
GAPDH for each replicate. The dashed line represents
mock-infected values. (C) Validation of the miR-99b target
site at ELF4 30 UTR andmiR-99b andmiR-485 target sites
at KLF8 30 UTR. HEK293T cells were co-transfected with
a psiCHECK-2 reporter plasmid, containing wild-type
(ELF4_wt, KLF8_wt) or mutated ELF4 or KLF8 30 UTRs
(ELF4_mut1, KLF8_mut1, and KLF8_mut2) at the 30 end
of the renilla gene, and the corresponding miRNA
expression plasmid (miRVec control, miRVec-99b, or
miRVec-485). Renilla and luciferase activities were eval-
uated 72 hr post-transfection. (D and E) Relative infective
viral particle release in control PANC-1 cells (Lenticrv2)
and three CRISPR/Cas9-modified PANC-1 clones for
ELF4 (D) and KLF8 (E). Cells were seeded in triplicate and
infected with AdwtE (0.5 IFU/cell). At 48 hr PI, superna-
tants were collected and titrated by viral infectious units.
The dashed line represents PANC-1 Lenticrv2 cells
values. For (A) and (B), data are shown as mean ± SEM for
at least three independent biological replicates. Signifi-
cance was assessed by comparison to mock-infected
cells using a one-sample t test and to infected cells using a
two-tailed Mann-Whitney test. For (C), data are shown as
mean ± SEM for at least three independent biological
replicates. Significance was assessed by comparison to
miRVec control-transfected cells using a one-sample
t test. For (D), data are shown as mean ± SEM for at least
five independent biological replicates. Significance was
assessed by comparison to PANC-1 Lenticrv2 cells using
a one-sample t test. *p < 0.05, **p < 0.01, ***p < 0.001.
www.moleculartherapy.orgneed for novel adenoviral designs with increased potency. miRNAs
have been shown to play a role in the progression of the adenoviral
cycle.9–11 However, it remains unclear how adenoviral replication is
affected by the extensively deregulated miRNA profile of tumor cells.
We hypothesized that, by expressing specific miRNAs, it would be
feasible to re-establish the levels of key cellular genes relevant for pro-
ductive viral infection, leading to improved adenoviral oncolysis.
Adenoviruses have the potential of being armed with sequences of in-
terest that provide additional functions. We performed an approach
based on the generation of an adenoviral miRNA library encoding
243 human miRNAs, followed by a replication-based bioselection
strategy that identified miR-99b and miR-485 as enhancers of the
adenoviral activity in pancreatic cancer cells. A similar strategy has
been previously used in the context of an in vivo alpha virus infection
to identify interactions between the virus and host factors impacting
viral replication.23 However, the designs of these approaches weresubstantially different, since they were not expressing specific
miRNAs but hairpin sequences designed to target unique murine
open reading frames. Our strategy is also distinct from that of a pre-
vious work studying miRNA effects on adenovirus propagation, in
which the modulation of miRNA content was dissociated from
adenoviral infection as miRNAs were introduced into cells 1 day
before adenoviral infection.11 Here, by incorporating the miRNAs
directly into the adenoviral genome, we were able to couple their
expression with the infection, forcing cancer cells to parse out those
factors that are important for the adenoviral replication cycle. The
temporal differences in cellular miRNA expression, and probably
the tumor model of pancreatic versus prostate cancer, may at least
partially explain the identification of different miRNAs regulating
adenoviral activity.
Our data show that miR-99b and miR-485 improved the intracellular
formation and led to the earlier release of infective virions, leading toMolecular Therapy Vol. 27 No 1 January 2019 237
A B
0,041 ± 0,010
0,0024 ± 0,004 (0,1775)
ICOVIR15
ICOVIR15 miR-99b
ICOVIR15 miR-485 0,0018 ± 0,003 (0,0173)












































































































































































Figure 6. miR-99b and miR-485 Confer Increased Oncolytic Activity and Enhanced Antitumoral Response to ICOVIR15
(A) Relative infective viral particle release. PANC-1 cells were seeded in triplicate and infected with ICOVIR15, ICOVIR15 miR-99b, or ICOVIR15 miR-485 (0.5 IFU/cell). At
48 hr PI, supernatants were collected and titrated by viral infectious units. The dashed line represents ICOVIR15 values. (B) In vitro oncolytic activity in PANC-1 cells. Cells
were seeded in triplicate and infected with a dose range of ICOVIR15, ICOVIR15 miR-99b, or ICOVIR15 miR-485. Cell viability was measured at 7 days PI by MTT assay and
(legend continued on next page)
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www.moleculartherapy.orgenhanced lytic effects. Changes in the expression of these two
miRNAs in response to viral infections have been documented for
other viruses. During an influenza virus infection, miR-485 expres-
sion increases in order to reduce RIG-1 levels and to diminish the
induction of downstream antiviral proteins.24 On the other hand,
miR-99 family members facilitate hepatitis B virus (HBV) replication
in hepatoma cells by increasing autophagic activity and by promoting
HBV protein production.25 Thus, miR-99b and miR-485 seem to
have a proviral function that supports their bioselection during our
screening strategy.
We observed that the infection of pancreatic cancer cells with AdwtE
miR-99b andAdwtEmiR-485was associatedwith higher expression of
viral genes encoding structural proteins (namely, hexon, penton, and
fiber) and the E1A gene, both at the RNA and protein levels, without
changes in the content of total viral genomes. This suggests that the
miR-99b and miR-485 effects were probably related to the transcrip-
tional activation of viral genes. This induction was superior in the
late genes, probably because the increase in E1A expression facilitates
the transactivation of late genes through its binding to the MLP.26
Through bioinformatics analysis, we identified potential miRNA
target genes for both miR-99b and miR-485 belonging to the tran-
scription factor family of proteins. In the current study, ELF4 was
validated as a target gene of miR-99b and KLF8 as that of both
miR-99b and miR-485. MDM2 has already been described as a vali-
dated target for miR-485. Infection of pancreatic cancer cells with
AdwtE miR-99b and AdwtE miR-485 resulted in decreased expres-
sion of these three proteins, in line with their regulation by miR-
99b and/or miR-485. Interestingly, MDM2 is an adenoviral limiting
factor.7,20,27 Importantly, we show that genetic downregulation of
ELF4 or KLF8 resulted in enhanced release of adenoviral particles,
pointing to a role for them in adenoviral activity modulation. KLF8
is a CACCC (GT-box)-binding dual-transcription factor, and its
binding sites have been identified at or next to the promoters of
different adenoviral genes, including two sites at the left ITR
(L-ITR) and two in the MLP. In this study, we could validate
that KLF8 reduces transcription from the adenoviral L-ITR/E1A
promoter and MLP. Promoter reporter assays showed higher tran-
scriptional activity in cells with downregulated KLF8 than in cells ex-
pressing KLF8 (Figure S8). These results support the view that,
through the recruitment of the C-terminal-binding protein (CtBP),
KLF8 represses the expression of these genes.28 Indeed, CtBP2 has
been previously identified as an adenoviral limiting factor.29,30
Furthermore, KLF8 recruits p300 and PCAF co-activators to pro-
moters.31 To promote productive virus infection, E1A removesIC50 values were determined. (C and D) Mice bearing subcutaneous PANC-1 tumors we
ICOVIR15miR-99b, or ICOVIR15miR-485 (C); or 4 1010 vp/animal of ICOVIR15, 2 1
(nR 7 tumors/treatment group). Samples were collected 35 days after treatment. Follo
**p < 0.01, ***p < 0.001. (E) qPCR analysis of E1A mRNA levels in PANC-1-treated tu
immunofluorescence of PANC-1-treated tumors (blue, DAPI; red, E1A). Representative i
independent biological replicates. Significance was assessed using a two-tailed Mann-CtBP2 from repressed promoters, sequesters p300 from transcrip-
tional active regions, and redirects it together with Rb to selected
host genes, thereby repressing their expression.29,32 In those cases,
high levels of KLF8 might compete with E1A and lead to reduced
adenoviral yields. ELF4 is an ETS transcription factor that becomes
activated during the antiviral response and in cells with oncogenic
Ras.33 ELF4 promotes MDM2 expression, which could explain, at
least in part, why MDM2 is downregulated in AdwtE miR-99b-in-
fected cells even though it is not a target for this miRNA.21 The ef-
fects of ELF4 on the adenoviral activity might be explained by its
regulation of MDM2. In fact, different hypotheses have been pro-
posed to explain MDM2 antiviral activity. MDM2 might send early
adenoviral proteins (E1A and E1B-55K) or cellular proteins
required for a productive viral cycle (PP2A) to proteasomal degra-
dation,27,34 but it can also induce the expression of CtBP235 or act as
a transcriptional repressor by interacting with the 34K subunit of
TFIIE.36 Thus, we propose that the downregulation of KLF8,
ELF4, and MDM2 through miR-99b or miR-485 expression pro-
motes the expression of the adenoviral late genes and E1A, which
in turn facilitates the adenoviral life cycle.
The expression of miR-99b and miR-485 may also provide pancreatic
cancer with tumor suppressor activities. Interestingly, we observed
that miR-99b and miR-485 were poorly expressed in PDAC samples
and that their reduced expression correlated with poorer survival
rates of patients. Thus, the enhanced antitumor activity of ICOVIR15
miR viruses might be the result of miR-99b andmiR-485 contributing
to improve the adenoviral fitness and their tumor-suppressive effects.
Our work was restricted to pancreatic cancer; however, other authors
have identified a contribution of miR-99b and miR-485 in the pro-
gression of different neoplasias. Low miR-99b expression has been
associated with advanced stages of glioma and with the presence of
lymphatic metastasis in cervical cancer.37,38 A metastatic inhibitor
role has been proposed for miR-485 in lung adenocarcinoma and
breast cancer.39,40 Also, low miR-485 expression has been found to
correlate with poor prognosis in gastric cancer.41 Moreover, high
expression levels of either KLF8 or ELF4 have been associated with
pro-tumorigenic processes, suggesting that their downregulation
may also be beneficial for controlling tumor growth.42–44 Altogether,
these findings indicate that the expression of miR-99b and miR-485
from the adenoviral genome produces a significant antitumor effect
as a consequence of the enhanced adenoviral activity, with a potential
contribution of their tumor suppressor activity. The similarities in
miR-99b and/or miR-485 alterations between cancer cells of different
origins allow us to speculate that the improved antitumoral response
of ICOVIR15-miR99b and ICOVIR15-miR-485 observed in PDACre intravenously administered with saline solution; 4  1010 vp/animal of ICOVIR15,
010 vp/animal of ICOVIR15miR-99b, or 2 1010 vp/animal of ICOVIR15miR-485 (D)
w-up of PANC-1 tumor volumes is represented as percentage of growth. *p < 0.05,
mors. mRNA values are expressed as relative to GAPDH in each replicate. (F) E1A
mages are shown; scale bar, 100 mm. Data are shown asmean ±SEM for at least five
Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001.
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PANC-1, MIA PaCa-2, Capan-2, HPAF-II, Hs766T, A549,
HEK293, and HEK293T cell lines were obtained from the Amer-
ican Type Culture Collection (ATCC). Luciferase-expressing cells
(CP15-Luc) were established by transducing the parental cell line
CP15 (derived from CP15 tumors) with a recombinant retrovirus
pLHCluc.45 NP-18 cells were established and provided by
Dr. Capellà.46 Cells were cultured in DMEM (Gibco-BRL) supple-
mented with 10% (v/v) fetal bovine serum (FBS), penicillin
(100 mg/mL), and streptomycin (100 mg/mL) (Gibco-BRL), and
they were maintained in a humidified atmosphere of 5% CO2 at
37C. Interspecies contamination and cell morphology were evalu-
ated by microscopic observation. Cell lines obtained from the
ATCC were immediately expanded and frozen. Every 2 months
cells were plated again from the original batch. Cells were not
authenticated by the authors. Interspecies contamination was
tested by PCR routinely.
Expression and Reporter Plasmids
miRVec plasmids were obtained from NKI human miRNA library
(miRLib) bacteria cells grown in Luria-Bertani broth (LB) containing
ampicillin (100 mg/mL). The miRLib library was generated by
Voorhoeve et al.47 and commercialized by Source BioScience
LifeSciences. psiCHECK-2_ELF4_wt, psiCHECK-2_ELF4_mut1,
psiCHECK-2_KLF8_wt, psiCHECK-2_KLF8_mut1, and psiCHECK-
2_KLF8_mut2 were generated by cloning the corresponding 30 UTR
fragments (genomic DNA: ELF4, 45,233–45654 bp; KLF8, 53,454–
54,679 bp) into psiCHECK-2 vector. The 30 UTR fragments contained
XhoI andNcoI restriction sites at their 50 and 30 ends, respectively, and
they were purchased as G-Blocks (Integrated DNA Technologies).
G-blocks were digested with XhoI and NcoI restriction enzymes
(Roche) and introduced into the psiCHECK-2 vector, digested with
the same restriction enzymes. Plasmid constructions were tested by
colony PCR and validated by Sanger sequencing using the primer
set 1 (Table S3).
Adenovirus Generation and Titration
pAdwtE hTR, pAdwtE miR-759, pICOVIR15 miR-99b, and
pICOVIR15 miR-485 were generated by an adapted recombineering
protocol, based on homologous recombination in bacteria using a
positive-negative selection screen with the RpsLNeo cassette.48,49
Primer sets used for the recombination step contain long tails homol-
ogous to the insertion point at the adenoviral genome (Table S3). The
RpsLNeo cassette was amplified by PCR from the pJetRpsL plasmid
(with primer set 2), and it was introduced by homologous recombina-
tion downstream of the adenoviral fiber gene at the adenoviral
genome (pAdwt). The EGFP gene was then amplified (with primer
set 3). The RpsLNeo cassette was replaced with the EGFP amplicon
by homologous recombination, generating the adenoviral genome
pAdwtE. The RpsLNeo cassette was then amplified by PCR from240 Molecular Therapy Vol. 27 No 1 January 2019the pJetRpsL plasmid (with primer set 4), and it was introduced
by homologous recombination 3 bp upstream of the R-ITR in the
reverse strand of the corresponding adenoviral genome (pAdwtE or
pICOVIR15).
Sequences encoding for hTR, miR-759, miR-99b, or miR-485, as
well as the CMV promoter regulating their expression, were ampli-
fied from the corresponding miRVec plasmid by PCR (with primer
set 5). The RpsLNeo cassette was replaced by each one of the
amplicons by homologous recombination. pAdwtE miRLib was
generated by replacing the RpsLNeo cassette with a mixture of
243 amplicons amplified from miRVec plasmids by PCR (with
primer set 5). Plasmid constructions were verified by PCR (with
primer sets 6 and 7), EcoRI enzymatic digestion, and Sanger
sequencing. The pAdwtE, pAdwtE hTR, pAdwtE miR-759,
pICOVIR15, pICOVIR15 miR-99b, and pICOVIR15 miR-485 plas-
mids were transfected into HEK293 cells to obtain a first round of
viral particles. Viruses were propagated in A549 cells and purified
by cesium chloride density gradient centrifugation according to
standard techniques.50 Adenoviral concentrations were calculated
based on optical density (vp/mL) or on viral infectious units
(IFU/mL), as previously described.51
AdwtEmiRLib Bioselection and Identification of Isolated Clones
pAdwtE miRLib plasmids were transfected in HEK293 cells to
obtain a first viral homogenate and titrated based on viral IFU, as
previously described.51 PANC-1 and MIA PaCa-2 cells were in-
fected with 1 IFU/cell and 5 IFU/cell of the viral homogenate,
respectively. When cytopathic effect (CPE) was observed, 10% of
the supernatant from PANC-1 and 30%–70% from MIA PaCa-2
were used to infect new cells; 20 rounds of infection were carried
out. Individual adenoviral clones were isolated by plaque assay in
PANC-1 cells (66 clones) or in A549 cells (45 clones) (for MIA
PaCa-2 bioselected viruses).52 Plaque assays from MIA PaCa-2 bio-
selected clones was carried out in A549 cells since MIA PaCa-2 cells
do not grow well at high confluency, a characteristic that is recom-
mended for plaque assay. The largest isolated clones were selected
and tested for miRNA identification. Encoded miRNAs were iden-
tified by Sanger sequencing using the primer set 7 (Table S3) in
the purified viral genomes.
Quantification of Viral Genomes and Infective Viral Particles
Cellular DNA and viral DNA were obtained from cellular extracts us-
ing UltraClean BloodSpin DNA Isolation Kit. Adenoviral genomes
were analyzed by qPCR on a ViiA7 System (Applied Biosystems), us-
ing SYBER Green I Master plus mix (Roche) and the primer set 4
(Table S4). The adenoviral copy number was quantified with a stan-
dard curve of adenovirus DNA dilutions (using 102–107 copies) in a
background of genomic DNA. Viral DNA was expressed relative to
the cellular DNA content, determined by qPCR using albumin 12
intron primers (primer set 5; Table S4) and a standard curve of
genomic DNA and corrected by the number of cells per well. Infective
viral particles were determined by viral DNA quantification in A549
at 4 hr PI.
www.moleculartherapy.orgmiRNA qRT-PCR
Total RNA was obtained from cell cultures using miRNeasy Mini
RNA Extraction Kit (QIAGEN). About 10 ng total RNA was reverse
transcribed using Applied Biosystems TaqMan MicroRNA Reverse
Transcription Kit and stem-loop primers (Thermo Fisher Scientific),
according to the manufacturers’ instructions. Applied Biosystems
TaqMan Universal PCR Master Mix No AmpErase UNG, qPCR
probes (Thermo Fisher Scientific), and 1.5 mL RT reaction were
used for the qPCR amplification reaction, performed as indicated
by the manufacturer. Expression data were normalized to small
nucleolar RNA U6 expression (RNU6B). The following stem-loop
primers and qPCR probes were purchased from Applied Biosystems
TaqMan MicroRNA Assay (Thermo Fisher Scientific): RNU6B
(001093), hsa-miR-99b* (002196), hsa-miR-99b (000436), hsa-miR-
485-3p (001277), and hsa-miR-485-5p (001036). Reactions were per-
formed on a ViiA7 System.
In Vivo Competition Assay
Subcutaneous tumors were generated in 8-week-old male athymic
nude Foxn 1nu nu/nu mice (ENVIGO) by injecting 2  106
PANC-1 or MIA PaCa-2 cells embedded in a ratio 1:1 of Matrigel
(BD Biosciences) into each flank. Tumors were measured
twice per week, and their volumes were calculated using the formula
V = D d2  pO6. Mice were randomly assigned to different
groups of treatment. Once tumor volume reached a median of
200 mm3, mice were intravenously administered a 1:1 mixture of
AdwtE:AdwtE miR-99b or AdwtE:AdwtE miR-485 (2  1010 vp/
animal). Animals were sacrificed 12 days after virus administration
and tumors were collected. To determine the number of infective par-
ticles of each virus, tumors were mechanically homogenized in PBS
1, followed by three freeze-thaw cycles. Cell debris was eliminated
by centrifugation, and a fraction of the supernatant was titrated (as
above) using specific primer sets for each virus (Table S2). The results
were corrected by the sample protein content, as determined by the
BCA Protein Assay Kit (Thermo Fisher Scientific). Animal proced-
ures met the guidelines of European Community Directive 86/609/
EEC and were approved by the Local Ethical Committee.
Antitumoral Efficacy Study
PANC-1 subcutaneous tumors were established as described above.
Mice were randomly assigned to different groups of treatment, and
they were intravenously administered with a single dose of saline so-
lution or virus (2 1010 or 4 1010 vp/animal) when tumor volumes
reached a median of 100 mm3. Tumors were measured twice per
week. Animals were euthanized 40 days after virus administration
and tumors were collected.
Statistical Analysis
Experimental data are represented by the mean ± SEM of at least
three independent experiments. Statistical analysis was performed
on GraphPad Prism version (v.)6.01. Statistical differences were eval-
uated using a 2-tailed non-parametric Mann-Whitney test or a one-
sample t test; p < 0.05 was taken as the level of significance. The in vivo
tumor growth statistical analysis was evaluated using R v.2.14.1 soft-ware with a linear mixed-effect model using the Ime4 package. Statis-
tical differences were evaluated using a multiple comparison of means
by Tukey contrasts; p < 0.05 was taken as the level of significance.
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